Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease

@article{Ross2001CurrentEF,
  title={Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease},
  author={George Webster Ross and Helen Petrovitch},
  journal={Drugs \& Aging},
  year={2001},
  volume={18},
  pages={797-806}
}
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting 1 to 3% of individuals over the age of 65 years. While effective therapy exists for treating the bradykinesia, rigidity and tremor associated with the disease, the cause is unknown. There is no treatment available to prevent or slow the progressive neuronal loss in the substantia nigra and associated decreased levels of dopamine in the striatum that underlie the cardinal features of the disease.Both… Expand
Multiple roles for nicotine in Parkinson's disease.
TLDR
Observations suggest that nAChR stimulation may represent a useful treatment strategy for Parkinson's disease for neuroprotection and symptomatic treatment, as only selective nA ChR subtypes are present in the striatum including the alpha4beta2*, alpha6beta2* and alpha7 nA cholinergic populations. Expand
Nicotine as a potential neuroprotective agent for Parkinson's disease
  • M. Quik, X. Perez, T. Bordia
  • Psychology, Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2012
TLDR
Findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease. Expand
Nicotine and Parkinson's disease: Implications for therapy
TLDR
Observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. Expand
Xanthine derivatives as agents affecting non-dopaminergic neuroprotection in Parkinson`s disease.
TLDR
The current review summarizes frequently suspected non-dopaminergic neuroprotective mechanisms and the possible beneficial effects of the xanthine derivatives in PD, along with some synthetic approaches to produce perspective xAnthine derivatives as non-Dopamin allergic agents in PD treatment. Expand
Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.
TLDR
It is demonstrated that caffeine administration for 1 month could attenuate the rotational behavior in lesioned rats and protect the neurons of SNC against 6-OHDA toxicity. Expand
Possible Anti-Parkinson’s Disease Therapeutics From Nature: A Review
TLDR
A review of the literature covering use of botanical-derived natural products, either as crude extracts or isolated compounds in monoherbal or polyherbal formulations, having anti-PD activity with notes on source plant, active component, experimental methodology, and ethnopharmacological relevance of anti- PD efficacy of the natural compounds. Expand
Nicotinic Receptor Intervention in Parkinson's Disease: Future Directions.
TLDR
The potential of nicotine in alleviating not only the motor symptoms, but also the mood disorders and mild cognitive impairments that are commonly co-morbid with PD will be presented and it is suggested that pulsatile nicotine administration (e.g. via inhalation or nasal spray) may be the optimal route in nicotinic intervention in PD. Expand
Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels
TLDR
Evaluating nicotine’s protective effect in a Drosophila melanogaster model for PD where Synphilin-1 (Sph-1) is expressed in dopaminergic neurons suggests that cholinergic agonists may promote survival and metabolic function of the dopamine neurons that express Sph-1. Expand
Characterisation of metabotropic glutamate receptor 4 as a therapeutic target in Parkinson's disease
TLDR
A systemically-administered agonist of mGluR4 showed promise in the treatment of neurodegeneration in an early-stage model of PD in rats and this agonist also has anti-Parkinsonian potential without causing dyskinesia, and is therefore a suitable and promising target for further research in PD. Expand
Therapeutic and Diagnostic Agents for Parkinson’s Disease
This chapter considers the biology and medical chemistry-based treatment of Parkinson’s disease, the second most common of the major neurodegenerative neuropsychiatric disorders. It surveys basicExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
The effects of nicotine on Parkinson's disease.
TLDR
Preliminary analysis shows improvements after acute nicotine in several areas of cognitive performance, particularly measures such as reaction time, central processing speed, and decreased tracking error, and improvements were seen in several motor measures suggesting improved extrapyramidal functioning. Expand
Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors
TLDR
The data suggest that the increase in neurotrophic factors is a possible mechanism by which (−)‐nicotine protects from experimental parkinsonisms. Expand
Nicotinic System Involvement in Alzheimer’s and Parkinson’s Diseases
TLDR
To maximise the potential benefit of long term treatment with nicotinic agonists (or other cholinergic drugs), it is suggested that drug treatment should be combined with cognitive rehabilitation strategies to enable patients and/or their families to focus on the particular cognitive domains that may be improved. Expand
Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease
TLDR
A potential neural basis for the inverse association of caffeine with the development of PD is established and the potential of A(2A) antagonists as a novel treatment for this neurodegenerative disease is enhanced. Expand
Nicotinic receptors and Parkinson's disease.
TLDR
The results show that nicotine pretreatment protected against dopaminergic nigral neural degeneration, and suggest that nicotinic receptor ligands may be useful in Parkinson's disease therapy. Expand
In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases.
TLDR
The results of these studies suggest that the beneficial/protective effects of nicotine in both Parkinson's disease and Alzheimer's disease may be, at least partly, due to antioxidant mechanisms. Expand
Theophylline increases “on” time in advanced parkinsonian patients
TLDR
The effect of the adenosine antagonist theophylline was tested in PD patients diagnosed with clinically definite idiopathic PD and divided into either early PD or advanced PD with l-dopa–induced motor side effects. Expand
Inhibition of monoamine oxidase B in the brains of smokers
TLDR
It is proposed that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking. Expand
Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases
TLDR
A range of neuroprotective strategies, including neurotrophic factors,Anti-excitotoxins, antioxidants, bioenergetic supplements, anti-apoptotics, immunosuppressants, and cell transplantation techniques are reviewed to hold promise as potential therapies in the treatment of Parkinson's and Huntington's diseases. Expand
Potential of Adenosine A2A Receptor Antagonists in the Treatment of Movement Disorders
TLDR
Preliminary studies in humans with nonselective adenosine receptor antagonists have indicated that this motor stimulant activity may extend to a reduction of the hypokinesia and tremor associated with Parkinson’s disease. Expand
...
1
2
3
4
5
...